Physician profile
Vinitha Vellanki
NPI 1427256700
$563.54
in general payments reported to CMS, 2019-2025
13 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $43.24 · 2021: $44.08 · 2022: $16.64 · 2023: $16.33 · 2024: $122 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $195.78 | 2024-2025 | Krystexxa, Tavneos, Repatha |
| Novo Nordisk INC | $76.61 | 2023-2025 | Ozempic, Rybelsus |
| Akebia Therapeutics INC | $63.47 | 2025 | Vafseo |
| Otsuka America Pharmaceutical, INC. | $41.85 | 2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $24.95 | 2020 | |
| Horizon Therapeutics Plc | $24.39 | 2021 | |
| Kyowa Kirin, INC. | $23.62 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.43 | 2024 | Jardiance |
| Lilly USA, LLC | $20.18 | 2025 | Mounjaro |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Mallinckrodt Hospital Products INC. | $18.29 | 2020 | |
| Abbott Laboratories | $16.64 | 2022 | |
| Calliditas Therapeutics US INC. | $15.64 | 2025 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinitha Vellanki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.